With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.

Suppr

超能文献

作者信息

Tuma Rabiya S

出版信息

J Natl Cancer Inst. 2007 Feb 7;99(3):192-4. doi: 10.1093/jnci/djk073.

DOI:10.1093/jnci/djk073

PMID:17284712

Abstract

摘要

相似文献

With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.

J Natl Cancer Inst. 2007 Feb 7;99(3):192-4. doi: 10.1093/jnci/djk073.

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.

J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145.

Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.

Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1.

Targeted cancer therapy: from bench to bedside to patient.

J Clin Oncol. 2014 Feb 1;32(4):268-70. doi: 10.1200/JCO.2013.53.8413. Epub 2013 Dec 23.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.

Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18.

BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.

Hong Kong Med J. 2009 Oct;15(5):365-73.

NICE backs leukaemia drug after manufacturer drops price.

BMJ. 2012 Mar 22;344:e2274. doi: 10.1136/bmj.e2274.

引用本文的文献

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).

Mol Cancer. 2012 Jun 21;11:42. doi: 10.1186/1476-4598-11-42.

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Mol Cancer. 2010 Apr 12;9:75. doi: 10.1186/1476-4598-9-75.

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

Blood. 2008 Aug 1;112(3):793-804. doi: 10.1182/blood-2007-10-116376. Epub 2008 May 27.

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验